Press Releases

Date Title and Summary
Toggle Summary Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome
Minutes Confirm Alignment on Soleno’s Planned Phase III Clinical Trial Soleno In Process of Initiating Phase III Study REDWOOD CITY, Calif. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the
Toggle Summary Soleno Therapeutics Announces $15 Million Private Placement
Financing to Support Planned Phase III Clinical Program for DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif. , Dec. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Toggle Summary Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology
REDWOOD CITY, Calif. , Dec. 08, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it, and its wholly-owned subsidiary, Capnia, Inc.
Toggle Summary Soleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will present a
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
Completed Successful EMA Meeting for DCCR in Prader-Willi Syndrome Continued Preparations to Begin Phase III Program Presented Positive Updated Safety and Efficacy Data from Pilot Clinical Trial of DCCR for Treatment of Prader-Willi Syndrome Regained Compliance with NASDAQ Listing Requirements
Toggle Summary Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements
REDWOOD CITY, Calif. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it received a notice from the NASDAQ Listing Qualifications Staff on October
Toggle Summary Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal
Toggle Summary Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome
REDWOOD CITY, Calif. , Oct. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent (9,782,416) from the U.S.
Toggle Summary Soleno Therapeutics Announces 1-for-5 Reverse Stock Split
Previously approved reverse stock split to be implemented on Friday, October 6, 2017 REDWOOD CITY, Calif. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today
Toggle Summary Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has received scientific advice  from the Committee for Medicinal